Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874738 | 0.84 | XDH (0.74) | XDHGDA | |
| SCHEMBL5935074 | 0.83 | XDH (0.78) | XDHGDA | |
| SCHEMBL9960821 | 0.83 | XDH (0.69) | XDHGDA | |
| SCHEMBL667798 | 0.81 | XDH (0.84) | XDHGDA | |
| SCHEMBL2343363 | 0.80 | XDH (0.65) | XDHGDA | |
| SCHEMBL3428514 | 0.80 | XDH (0.65) | XDHGDA | |
| SCHEMBL9170843 | 0.80 | XDH (0.52) | XDHGDA | |
| SCHEMBL29374626 | 0.79 | XDH (0.54) | XDHGDA | |
| SCHEMBL16093685 | 0.79 | XDH (0.64) | XDHGDA | |
| SCHEMBL6272738 | 0.79 | XDH (1.00) | XDHGDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | claimed |
| EP-3080289-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-10-19 | — | — | EP | claimed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| WO-2015196128-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | claimed |
| EP-2931319-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | claimed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | claimed |
| EP-0977767-B1 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2007-09-19 | — | — | EP | claimed |
| CN-120148639-A | Method, system and storage medium for identifying downstream exercise factors for regulating brown fat metabolism | 北京体育大学 | 2025-06-13 | — | — | CN | disclosed |
| CN-118510522-A | Conjugated oligonucleotides and uses thereof | IONIS制药公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| CN-1279687-A | Oligonucleotide analogues | EXIQON AS (DK) | 2001-01-10 | — | — | CN | disclosed |
| US-5252482-A | Precursor of a C-terminal amidated calcitonin | SUNTORY LIMITED (JP) | 1993-10-12 | — | — | US | disclosed |
| EP-0095351-B1 | A PRECURSOR OF A C-TERMINAL AMIDATED PEPTIDE AND PRODUCTION THEREOF | SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) | 1989-11-08 | — | — | EP | disclosed |
| EP-0095351-A2 | A precursor of a C-terminal amidated peptide and production thereof | SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) | 1983-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | XDH 2049/4885GDA 36/4885 |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | XDH 2049/4885GDA 36/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | XDH 1523/4885GDA 83/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | XDH 1523/4885GDA 83/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | XDH 2049/4885GDA 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.